September 23, 2020
Finch Therapeutics Raises $90 Million for Microbiome Medication
Finch Therapeutics Group has raised $90 million to push its oral microbiome drug to treat recurrent C. difficile infection toward a regulatory submission with the FDA. The money raised will also be used to initiate a Phase 1b study evaluating a similar drug for autism spectrum disorder, as well as to advance treatments for chronic hepatitis B infection, ulcerative colitis and Crohn’s disease.
